First human test of new cancer drug combo begins
NCT ID NCT06487858
Summary
This is a very early-stage study to test the safety and initial effects of a new drug called BGB-R046. It will be given alone and in combination with an existing immunotherapy drug (tislelizumab) to about 75 people with advanced solid tumors that have spread and no longer respond to standard treatments. The main goal is to find a safe dose and see if the treatment shows any signs of helping to control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Cancer Hospital
Fuzhou, Fujian, 350014, China
-
Guangxi Medical University Cancer Hospital
Nanning, Guangxi, 530021, China
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Jining No1 Peoples Hospital West Branch
Jining, Shandong, 272000, China
-
Shanghai Pulmonary Hospital
Shanghai, Shanghai Municipality, 200433, China
-
The First Hospital of China Medical University
Shenyang, Liaoning, 110001, China
-
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, 430022, China
-
West China Hospital, Sichuan University
Chengdu, Sichuan, 610041, China
Conditions
Explore the condition pages connected to this study.